 -Participants with SR-aGVHD disease achieved an ORR of 67 and CR of 17 as measured by best response- -Participants with TR-aGVHD 11 of 12 concomitant ruxolitinib achieved an ORR of 67 and CR of 25 at Day 28- -Median survival benefits in TR-aGVHD participants compare favorably to historical controlsneihulizumab was well tolerated, with similar safety ... The post AltruBio Presents New Positive Data from its Completed Phase 1b Study Evaluating ALTB-168 in Patients with Steroid-Refractory or... 